The Measurement of Nitric Oxide and Its Metabolites in Biological Samples by Ozone-Based Chemiluminescence

Pinder, Andrew G.; Rogers, Stephen C.; Khalatbari, Afshin; Ingram, Thomas E.; James, Philip E.

doi:10.1007/978-1-59745-129-1_2

Cited by 51 publications

(59 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certainly in our hands [13] there remains noticeable variation in both time to peak, and peak plasma [ . It is tempting to speculate this reflects mainly differences in dealing with and/or storing the plasma sample as we and others have demonstrated [15]. There is no observable trend to indicate higher baseline plasma levels influence the peak yield, but this remains to be tested directly.…”

Section: Individual Versus Group Variationmentioning

confidence: 80%

Nitrate pharmacokinetics: Taking note of the difference

et al. 2015

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Individual Versus Group Variationmentioning

confidence: 80%

Nitrate pharmacokinetics: Taking note of the difference

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, at least one solvent filter should be placed in-line between the condenser and the NOA (Whatman, solvent IFD). The condenser(s) and filter(s) ensure that the gas stream from the purge vessel to the NOA is as dry as possible [10], eliminating any possible quenching of NO • signal by water vapor [17], while also protecting the NOA reaction cell from moisture and possible damage [18]. The condenser also optimizes the NO • + O 3 reaction in the NOA, which is reduced at higher temperatures [19].…”

Section: 0 Materials and Methodsmentioning

confidence: 99%

“…It exploits the luminescent nature of the reaction between NO • and O 3 [18]. An O 2 source tank is used to generate O 3 in the NOA reaction cell [18].…”

Section: 0 Materials and Methodsmentioning

confidence: 99%

“…It exploits the luminescent nature of the reaction between NO • and O 3 [18]. An O 2 source tank is used to generate O 3 in the NOA reaction cell [18]. O 3 subsequently reacts with NO • , generating nitrogen dioxide (NO 2 ), a portion of which arises in an electronically excited state (NO 2 *) (reaction [5]) [21].…”

Section: 0 Materials and Methodsmentioning

confidence: 99%

“…The success of this assay in preventing heme autocapture of NO • in the purge vessel necessitates full saturation of the cooper cysteine reagent with CO. This requires the purge vessel pressure to be maintained at approximately 120 Torr above atmospheric pressure [3, 10, 18]. This headspace pressure ensures that the heme interacts with CO rather than NO • , despite its greater affinity for NO • over CO [31, 32].…”

Section: 0 Materials and Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Analysis of S-nitrosothiols via copper cysteine (2C) and copper cysteine – Carbon monoxide (3C) methods

Rogers¹,

Gibbons²,

Griffin³

et al. 2013

Methods

Self Cite

View full text Add to dashboard Cite

This chapter summarizes the principles of RSNO measurement in the gas phase, utilizing ozone-based chemiluminescence and the copper cysteine (2C) ± carbon monoxide (3C) reagent. Although an indirect method for quantifying RSNOs, this assay represents one of the most robust methodologies available. It exploits the NO• detection sensitivity of ozone based chemiluminscence, which is within the range required to detect physiological concentrations of RSNO metabolites. Additionally, the specificity of the copper cysteine (2C and 3C) reagent for RSNOs negates the need for sample pretreatment, thereby minimizing the likelihood of sample contamination (false positive results), NO species inter-conversion, or the loss of certain highly labile RSNO species. Herein, we outline the principles of this methodology, summarizing key issues, potential pitfalls and corresponding solutions.

show abstract

Cardiovascular bioimaging of nitric oxide: Achievements, challenges, and the future

Vidanapathirana

Psaltis

Bursill

et al. 2020

Medicinal Research Reviews

View full text Add to dashboard Cite

Nitric oxide (NO) is a ubiquitous, volatile, cellular signaling molecule that operates across a wide physiological concentration range (pM–µM) in different tissues. It is a highly diffusible messenger and intermediate in various metabolic pathways. NO plays a pivotal role in maintaining optimum cardiovascular function, particularly by regulating vascular tone and blood flow. This review highlights the need for accurate, real‐time bioimaging of NO in clinical diagnostic, therapeutic, monitoring, and theranostic applications within the cardiovascular system. We summarize electrochemical, optical, and nanoscale sensors that allow measurement and imaging of NO, both directly and indirectly via surrogate measurements. The physical properties of NO render it difficult to accurately measure in tissues using direct methods. There are also significant limitations associated with the NO metabolites used as surrogates to indirectly estimate NO levels. All these factors added to significant variability in the measurement of NO using available methodology have led to a lack of sensors and imaging techniques of clinical applicability in relevant vascular pathologies such as atherosclerosis and ischemic heart disease. Challenges in applying current methods to biomedical and clinical translational research, including the wide physiological range of NO and limitations due to the characteristics and toxicity of the sensors are discussed, as are potential targets and modifications for future studies. The development of biocompatible nanoscale sensors for use in combination with existing clinical imaging modalities provides a feasible opportunity for bioimaging NO within the cardiovascular system.

show abstract

The Measurement of Nitric Oxide and Its Metabolites in Biological Samples by Ozone-Based Chemiluminescence

Cited by 51 publications

References 6 publications

Nitrate pharmacokinetics: Taking note of the difference

Nitrate pharmacokinetics: Taking note of the difference

Analysis of S-nitrosothiols via copper cysteine (2C) and copper cysteine – Carbon monoxide (3C) methods

Cardiovascular bioimaging of nitric oxide: Achievements, challenges, and the future

Contact Info

Product

Resources

About